4D Molecular Therapeutics (FDMT) stock, explained like you're 5

Is 4D Molecular Therapeutics a small, medium or large cap company?

No. 4D Molecular Therapeutics is a small cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 736 million dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How 4D Molecular Therapeutics makes money

• Selling medicines, medical devices or healthcare services.
• Insurance premiums or hospital and clinic fees.
• Research and licensing deals.

What moves FDMT stock

• Results from clinical trials and approvals from regulators.
• Drug prices, insurance rules and government policy.
• Patents running out and new competing treatments.

In the news lately

• Price Driven Insight from (FDMT) for Rule Based Strategy (Stock Traders Daily)
• OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs (Stocktwits)
• 4D Molecular Therapeutics (NasdaqGS:FDMT) Stock Forecast & Analyst Predictions (Simply Wall Street)
• 4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates (Yahoo Finance)
• Four retinal specialists will join company leaders in New York to discuss retinal disease treatment. (Stock Titan)

Key terms to know before you follow FDMT

• Market cap
• P/E ratio
• EPS (earnings per share)
• Earnings report
• Volatility